The 60-min time point prior to hypoglycemia for SSTR2 antagonist drug dosing was selected in these studies based on the previously reported PK/PD results for PRL-2903 and ZT-01 (Farhat et al., 2022), showing peak plasma drug levels were achieved −2 h after subcutaneous injection, and that glucagon levels increase within 60 min of treatment (as also observed in this study, at 30 min post-dose). The gene discussed is SSTR2; the disease is Hypoglycemia.